Skip to content

Pivotal bioVenture Partners Investment Advisor LLC

Follow

13F filer, CIK 1844645, SAN FRANCISCO, CA

Pivotal bioVenture Partners Investment Advisor LLC reported $251,770,820 across 14 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-13. Its ten largest share positions make up 91.13% of the portfolio.

Accepted , ingested 13F-HR 0001012975-26-001045

Period
2026-09-30
Reported value
$252M
Holdings
14
Top 10 weight
91.13%
New
2
Sold out
1

Largest buys vs the previous quarter

SecurityShares changeApprox. value
OBXnew+860,343$11.8M
BRVEnew+317,351$6.41M
OCSadded+152,657$1.43M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
ZBIOreduced-257,590-$6.95M
ARQTreduced-257,109-$6.8M
AVLNreduced-100,000-$2.85M
RXRXexited-595,518-$2.19M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001012975-26-001045, largest first. % of portfolio is the value over $251,770,820, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PCVXVAXCYTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 703,834 shares; 2025Q1: 710,734 shares; 2025Q2: 1,305,125 shares; 2025Q3: 1,372,425 shares; 2025Q4: 1,372,425 shares; 2026Q1: 1,372,425 shares; 2026Q2: 1,425,470 shares; 2026Q3: 1,425,470 shares 1,425,470$81.1M32.22%0Timeline
ARQTARCUTIS BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,120,508 shares; 2025Q1: 2,120,508 shares; 2025Q2: 2,120,508 shares; 2025Q3: 2,120,508 shares; 2025Q4: 1,366,624 shares; 2026Q1: 1,355,892 shares; 2026Q2: 1,265,283 shares; 2026Q3: 1,008,174 shares 1,008,174$26.6M10.58%-257,109Timeline
TRVITREVI THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,146,110 shares; 2025Q3: 1,256,782 shares; 2025Q4: 1,256,782 shares; 2026Q1: 1,553,726 shares; 2026Q2: 1,742,672 shares; 2026Q3: 1,742,672 shares 1,742,672$25M9.91%0Timeline
AVLNAVALYN PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 966,792 shares; 2026Q3: 866,792 shares 866,792$24.7M9.81%-100,000Timeline
EVMNEVOMMUNE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,926,943 shares; 2026Q1: 1,926,943 shares; 2026Q2: 1,926,943 shares; 2026Q3: 1,926,943 shares 1,926,943$15.9M6.32%0Timeline
IMNMIMMUNOME INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 502,512 shares; 2025Q4: 732,512 shares; 2026Q1: 732,512 shares; 2026Q2: 732,512 shares; 2026Q3: 732,512 shares 732,512$15.8M6.26%0Timeline
OCSOCULIS HOLDING AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,737,696 shares; 2025Q1: 2,300,774 shares; 2025Q2: 2,300,774 shares; 2025Q3: 2,300,774 shares; 2025Q4: 2,288,658 shares; 2026Q1: 1,680,283 shares; 2026Q2: 1,506,250 shares; 2026Q3: 1,658,907 shares 1,658,907$15.5M6.15%+152,657Timeline
OBXOBSIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 860,343 shares 860,343$11.8M4.69%newTimeline
AVTXAVALO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 295,933 shares; 2026Q2: 434,033 shares; 2026Q3: 434,033 shares 434,033$6.65M2.64%0Timeline
BRVEBRAVEHEART BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 317,351 shares 317,351$6.41M2.55%newTimeline
ZBIOZENAS BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 736,645 shares; 2025Q1: 736,645 shares; 2025Q2: 779,045 shares; 2025Q3: 779,045 shares; 2025Q4: 591,991 shares; 2026Q1: 591,991 shares; 2026Q2: 490,766 shares; 2026Q3: 233,176 shares 233,176$6.29M2.5%-257,590Timeline
MPLTMAPLIGHT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 611,447 shares; 2026Q1: 611,447 shares; 2026Q2: 611,446 shares; 2026Q3: 611,446 shares 611,446$6.23M2.47%0Timeline
RLYBRALLYBIO CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 300,579 shares; 2026Q2: 300,579 shares; 2026Q3: 300,579 shares 300,579$5.17M2.05%0Timeline
BIOABIOAGE LABS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 653,374 shares; 2025Q1: 653,374 shares; 2025Q2: 653,374 shares; 2025Q3: 653,374 shares; 2025Q4: 653,374 shares; 2026Q1: 653,374 shares; 2026Q2: 653,374 shares; 2026Q3: 653,374 shares 653,374$4.63M1.84%0Timeline

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
RXRXRECURSION PHARMACEUTICALS IN595,518$2.19Mshares

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001012975-26-001045 base2026-11-13